The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kryukov A.I.

Sverzhevsky Research Clinical Institute of Otorhinolaryngology

Ivoilov A.Yu.

Sverzhevsky Research Clinical Institute of Otorhinolaryngology

Mileshina N.A.

Russian Medical Academy for Continuous Professional Education

Danilevskaya N.S.

Sverzhevsky Research Clinical Institute of Otorhinolaryngology

Polunin M.M.

Pirogov Russian National Research Medical University

Simonova O.I.

National Medical Research Center for Children’s Health;
Sechenov First Moscow State Medical University (Sechenov University);
Morozovskaya Pediatric Municipal Clinical Hospital

Meshcheryakov K.L.

National Medical Research Center for Children’s Health

Sokolova V.N.

National Medical Research Center for Children’s Health

Kashirskaya N.Yu.

Bochkov Medical and Genetic Research Center

Zinchenko R.A.

Bochkov Medical and Genetic Research Center

Barilyak V.V.

Doctor Hearing LLC

Hearing impairment in children with cystic fibrosis

Authors:

Kryukov A.I., Ivoilov A.Yu., Mileshina N.A., Danilevskaya N.S., Polunin M.M., Simonova O.I., Meshcheryakov K.L., Sokolova V.N., Kashirskaya N.Yu., Zinchenko R.A., Barilyak V.V.

More about the authors

Journal: Russian Bulletin of Otorhinolaryngology. 2026;91(1): 41‑49

DOI: 10.17116/otorino20269101141

Read: 529 times

Buy for 300₽
Contact the author
Table of contents

HEARING IMPAIRMENT IN CHILDREN WITH CYSTIC FIBROSIS
HEARING IMPAIRMENT IN CHILDREN WITH CYSTIC FIBROSIS

To cite this article:

Kryukov AI, Ivoilov AYu, Mileshina NA, et al. Hearing impairment in children with cystic fibrosis. Russian Bulletin of Otorhinolaryngology. 2026;91(1):41‑49. (In Russ.)
https://doi.org/10.17116/otorino20269101141

Подписка 2026 Вестник оториноларингологии (Russian Bulletin of Otorhinolaryngology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Recommended articles:
Correlation between endo­thelial dysfunction and sensorineural hearing loss. Russian Bulletin of Otorhinolaryngology. 2025;(3):13-18
Intralabyrinthine schwannoma masking as Meniere’s disease. Russian Bulletin of Otorhinolaryngology. 2025;(3):67-72
The effe­ctiveness of adequate correction of audi­tory function on cognitive function. Russian Bulletin of Otorhinolaryngology. 2025;(4):105-111
Speech audiometry is an effe­ctive method for dete­rmining speech inte­lligibility in children using cochlear implantation systems. Russian Bulletin of Otorhinolaryngology. 2025;(5):23-30
Features of the pronunciation in school-age children with mini­mal hearing impairment. Russian Bulletin of Otorhinolaryngology. 2026;(1):22-28
Elevated ABR thre­sholds in the presence of otoacoustic emissions: case series. Russian Bulletin of Otorhinolaryngology. 2026;(1):76-85
Pathomorphology of chro­nic poly­pous puru­lent rhinosinusitis in cystic fibrosis in children. Russian Rhinology. 2025;(2):101-110
Sino­nasal pathology in patients with primary ciliary dyskinesia. Russian Rhinology. 2025;(3):223-232
History of the use of CFTR modu­lators in the treatment of cystic fibrosis. Journal of Respiratory Medi­cine. 2025;(3):40-50
Abstract:

The process of hearing impairment in children suffering from cystic fibrosis remains one of the pressing problems for the scientific medical community today. The article examines the effect of systemic antibacterial therapy with aminoglycoside antibiotics on the auditory function of children with cystic fibrosis.

OBJECTIVE

To analyze the causes of hearing loss and the causes of hearing impairment in children with cystic fibrosis from antibacterial therapy with aminoglycoside antibiotics.

MATERIAL AND METHODS

Search for literature sources using the search engines PubMed, Web of Science and eLibrary.

RESULTS

A review of the literature shows that the acute problem of sensorineural hearing loss is associated with frequent use of aminoglycosides, and predictors of conductive hearing loss are inflammatory processes in the middle ear and eustachian tube. It has been demonstrated that not in all cases, antibacterial therapy with aminoglycoside antibiotics leads to hearing impairment, which demonstrates the urgent need to study the auditory function of children with cystic fibrosis and identify the characteristics of hearing impairment.

Keywords:

cystic fibrosis
aminoglycosides
sensorineural hearing loss
conductive hearing loss
hearing impairment in children

Authors:

Kryukov A.I.

Sverzhevsky Research Clinical Institute of Otorhinolaryngology

Ivoilov A.Yu.

Sverzhevsky Research Clinical Institute of Otorhinolaryngology

Mileshina N.A.

Russian Medical Academy for Continuous Professional Education

Danilevskaya N.S.

Sverzhevsky Research Clinical Institute of Otorhinolaryngology

Polunin M.M.

Pirogov Russian National Research Medical University

Simonova O.I.

National Medical Research Center for Children’s Health;
Sechenov First Moscow State Medical University (Sechenov University);
Morozovskaya Pediatric Municipal Clinical Hospital

Meshcheryakov K.L.

National Medical Research Center for Children’s Health

Sokolova V.N.

National Medical Research Center for Children’s Health

Kashirskaya N.Yu.

Bochkov Medical and Genetic Research Center

Zinchenko R.A.

Bochkov Medical and Genetic Research Center

Barilyak V.V.

Doctor Hearing LLC

Received:

22.04.2025

Accepted:

22.08.2025

Close metadata

References:

  1. Kashirskaya NYu, Kapranov NI, Kondrat’eva EI. Mukovistsidoz. Monografiya. Izdanie 2-e, pererabotannoe i dopolnennoe. M.: Medpraktika; 2021. (In Russ.).
  2. Garinis AC, Poling GL, Rubenstein RC, Konrad-Martin D, Hullar TE, Baguley DM, Burrows HL, Chisholm JA, Custer A, Hawe LD, Hunter LL, Marras TK, Ortiz CE, Petersen L, Steyger PS, Winthrop K, Zettner EM, Clark K, Hungerford M, Vachhani JJ, Brewer CC. Clinical Considerations for Routine Auditory and Vestibular Monitoring in Patients with Cystic Fibrosis. American Journal of Audiology. 2021;30(3S):800-809.  https://doi.org/10.1044/2021_aja-21-00031
  3. Scotet V, L’Hostis C, Férec C. The Changing Epidemiology of Cystic Fibrosis: Incidence, Survival and Impact of the CFTR Gene Discovery. Genes. 2020;11(6):589.  https://doi.org/10.3390/genes11060589
  4. Wu M, Davis JD, Zhao C, Daley T, Oliver KE. Racial inequities and rare CFTR variants: impact on cystic fibrosis diagnosis and treatment. Journal of Clinical and Translational Endocrinology. 2024;36:100344. https://doi.org/10.1016/j.jcte.2024.100344
  5. Guo J, Garratt A, Hill A. Worldwide rates of diagnosis and effective treatment for cystic fibrosis. Journal of Cystic Fibrosis. 2022;21(3):456-462.  https://doi.org/10.1016/j.jcf.2022.01.009
  6. Sosnay PR, Raraigh KS, Gibson RL. Molecular Genetics of Cystic Fibrosis Transmembrane Conductance Regulator: Genotype and Phenotype. Pediatric Clinics of North America. 2016;63:585-598.  https://doi.org/10.1016/j.pcl.2016.04.002
  7. Farrell PM, White TB, Howenstine MS, Munck A, Parad RB, Rosenfeld M, Sommerburg O, Accurso FJ, Davies JC, Rock MJ, Sanders DB, Wilschanski M, Sermet-Gaudelus I, Blau H, Gartner S, McColley SA. Diagnosis of Cystic Fibrosis in Screened Populations. The Journal of Pediatrics. 2017;181S:S33-S44.  https://doi.org/10.1016/j.jpeds.2016.09.065
  8. Castellani C, Cuppens H, Macek M Jr, Cassiman JJ, Kerem E, Durie P, Tullis E, Assael BM, Bombieri C, Brown A, Casals T, Claustres M, Cutting GR, Dequeker E, Dodge J, Doull I, Farrell P, Ferec C, Girodon E, Johannesson M, Kerem B, Knowles M, Munck A, Pignatti PF, Radojkovic D, Rizzotti P, Schwarz M, Stuhrmann M, Tzetis M, Zielenski J, Elborn JS. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. Journal of Cystic Fibrosis. 2008;7:179-196.  https://doi.org/10.1016/j.jcf.2008.03.009
  9. Registr bol’nykh mukovistsidozom v Rossijskoj Federatsii. 2017 god. M.: Medpraktika-M; 2019. (In Russ.).
  10. Petrova NV, Kashirskaya NY, Vasilyeva TA, Timkovskaya EE, Voronkova AY, Shabalova LA, Kondratyeva EI, Sherman VD, Novoselova OG, Kapranov NI, Zinchenko RA, Ginter EK, Makaov AKh, Kerem B. High prevalence of W1282x mutation in cystic fibrosis patients from Karachay-Cherkessia. Journal of Cystic Fibrosis. 2016;15:e28-e32.  https://doi.org/10.1016/j.jcf.2016.02.003
  11. Petrova NV, Kashirskaya NY, Saydaeva DK, Polyakov AV, Adyan TA, Simonova OI, Gorinova YV, Kondratyeva EI, Sherman VD, Novoselova OG, Vasilyeva TA, Marakhonov AV, Macek M Jr, Ginter EK, Zinchenko RA. Spectrum of CFTR mutations in Chechen cystic fibrosis patients: High frequency of c.1545_1546delTA (p.Tyr515X; 1677delTA) and c.274G>A (p.Glu92Lys, E92K) mutations in North Caucasus. BMC Medical Genetics. 2019;20:44.  https://doi.org/10.1186/s12881-019-0785-z
  12. Paranjapye A, Ruffin M, Harris A, Corvol H. Genetic variation in CFTR and modifier loci may modulate cystic fibrosis disease severity. Journal of Cystic Fibrosis. 2020;19(Suppl 1):S10-S14.  https://doi.org/10.1016/j.jcf.2019.11.001
  13. Bobadilla J L, Macek M, Jr, Fine J P, Farrell P M. Cystic fibrosis: a worldwide analysis of CFTR mutations — correlation with incidence data and application to screening. Human Mutation. 2002;19(6):575-606.  https://doi.org/10.1002/humu.10041
  14. Vanscoy LL, Blackman SM, Collaco JM, Bowers A, Lai T, Naughton K, Algire M, McWilliams R, Beck S, Hoover-Fong J, Hamosh A, Cutler D, Cutting GR. Heritability of lung disease severity in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine. 2007;175(10):1036-1043. https://doi.org/10.1164/rccm.200608-1164OC
  15. Knowles MR, Drumm M. The influence of genetics on cystic fibrosis phenotypes. Cold Spring Harbor Perspectives in Medicine. 2012;2(12):009548. https://doi.org/10.1101/cshperspect.a009548
  16. Mafficini A, Ortombina M, Sermet-Gaudelius I, Lebecque P, Leal T, Iansa P, Reychler G, Dahan K, Pepermans X, Lenoir G, Leonard A, Sorio C, Assael B, Melotti P. Impact of polymorphism of multidrug resistance-associated protein 1 (ABCC1) gene on the severity of cystic fibrosis. Journal of Cystic Fibrosis. 2011;10(4):228-233.  https://doi.org/10.1016/j.jcf.2010.10.007
  17. Ideozu JE, Zhang X, Pan A, Ashrafi Z, Woods KJ, Hessner MJ, Simpson P, Levy H. Increased expression of plasma-induced ABCC1 mRNA in cystic fibrosis. International Journal of Molecular Sciences. 2017;18(8):1752. https://doi.org/10.3390/ijms18081752
  18. Yokoyama E, Chávez-Saldaña M, Orozco L, Cuevas F, Lezana JL, Vigueras-Villaseñor RM, Rojas-Castañeda JC, Landero DA. Influence of SNPs in genes that modulate lung disease severity in a group of Mexican patients with cystic fibrosis. Archives of Medical Research. 2018;49(1):18-26.  https://doi.org/10.1016/j.arcmed.2018.04.010
  19. Marson FA, Bertuzzo CS, Ribeiro AF, Ribeiro JD. Polymorphisms in ADRB2 gene can modulate the response to bronchodilators and the severity of cystic fibrosis. BMC Pulmonary Medicine. 2012;12:50.  https://doi.org/10.1186/1471-2466-12-50
  20. Marson FAL, Bertuzzo CS, Hortencio TDR, Ribeiro JD, Bonadia LC, Ribeiro AF. The ACE gene D/I polymorphism as a modulator of severity of cystic fibrosis. BMC Pulmonary Medicine. 2012;12(1):41.  https://doi.org/10.1186/1471-2466-12-41
  21. Gong J, Wang F, Xiao B, Panjwani N, Lin F, Keenan K, Avolio J, Esmaeili M, Zhang L, He G, Soave D, Mastromatteo S, Baskurt Z, Kim S, O’Neal WK, Polineni D, Blackman SM, Corvol H, Cutting GR, Drumm M, Knowles MR, Rommens JM, Sun L, Strug LJ. Genetic association and transcriptome integration identify contributing genes and tissues at cystic fibrosis modifier loci. PLoS Genetics. 2019;15(2):e1008007. https://doi.org/10.1371/journal.pgen.1008007
  22. Sofia VM, Surace C, Terlizzi V, Da Sacco L, Alghisi F, Angiolillo A, Braggion C, Cirilli N, Colombo C, Di Lullo A, Padoan R, Quattrucci S, Raia V, Tuccio G, Zarrilli F, Tomaiuolo AC, Novelli A, Lucidi V, Lucarelli M, Castaldo G, Angioni A. Trans-heterozygosity for mutations enhances the risk of recurrent/chronic pancreatitis in patients with cystic fibrosis. Molecular Medicine. 2018;24(1):38.  https://doi.org/10.1186/s10020-018-0041-6
  23. Smith DJ, Klein K, Hartel G, Wainwright CE, Bell SC, Anderson GJ, Reid DW. Mutations in the HFE gene can be associated with increased lung disease severity in cystic fibrosis. Gene. 2019;683:12-17.  https://doi.org/10.1016/j.gene.2018.10.002
  24. Henderson LB, Doshi VK, Blackman SM, Naughton KM, Pace RG, Moskovitz J, Knowles MR, Durie PR, Drumm ML, Cutting GR. Variation in MSRA modifies risk of neonatal intestinal obstruction in cystic fibrosis. PLoS Genetics. 2012;8(3):e1002580. https://doi.org/10.1371/journal.pgen.1002580
  25. Boëlle PY, Debray D, Guillot L, Corvol H, French CF. Modifier Gene Study Investigators SERPINA1 Z allele is associated with cystic fibrosis liver disease. Genetics in Medicine. 2019;21(9):2151-2155. Epub 2019 Feb 11. PMID: 30739910. https://doi.org/10.1038/s41436-019-0449-6
  26. Boëlle PY, Debray D, Guillot L, Clement A, Corvol H, French CF. Modifier Gene Study Investigators Cystic fibrosis liver disease: outcomes and risk factors in a large cohort of French patients. Hepatology. 2019;69(4):1648-1656. https://doi.org/10.1002/hep.30148
  27. Strug LJ, Gonska T, He G, Keenan K, Ip W, Boëlle PY, Lin F, Panjwani N, Gong J, Li W, Soave D, Xiao B, Tullis E, Rabin H, Parkins MD, Price A, Zuberbuhler PC, Corvol H, Ratjen F, Sun L, Bear CE, Rommens JM. Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics. Human Molecular Genetics. 2016;25(20):4590-4600. PMID: 28171547; PMCID: PMC5886039. https://doi.org/10.1093/hmg/ddw290
  28. Klinicheskie rekomendatsii. Kistoznyj fibroz (mukovistsidoz). 2021. (In Russ.). Accessed December 22, 2025. https://disuria.ru/_ld/11/1113_kr21E84MZ.pdf
  29. Chen Q, Shen Y, Zheng J. A review of cystic fibrosis: Basic and clinical aspects. Animal Models and Experimental Medicine. 2021; 4(3):220-232.  https://doi.org/10.1002/ame2.12180
  30. Ledeneva LN, Vodovozova EV, Grigoryants IS, Belash TA, Enina EA, Pustabaeva MS. The role of neonatal screening in the diagnosis and detection of cystic fibrosis in the Stavropol Territory. Rossijskij vestnik perinatologii i pediatrii. 2021;66(4):290-291. (In Russ.).
  31. Cystic Fibrosis Foundation. Patient Registry Annual Data Report. 2017. Accessed December 22, 2025. https://www.researchgate.net/figure/Cystic-Fibrosis-Foundation-Patient-Registry-2017-Annual-Data-Report-Bethesda-Maryland_fig1_344366258
  32. Conway SP, Miller MG, Ramsden C, Littlewood JM. Intensive treatment of pseudomonas chest infection in cystic fibrosis: A comparison of tobramycin and ticarcillin, and netilmicin and ticarcillin. Acta Pediatrica. 1985;74(1):107-113.  https://doi.org/10.1111/j.1651-2227.1985.tb10929.x
  33. Barclay ML, Begg EJ, Chambers ST, Thornley PE, Pattemore PK, Grimwood K. Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis. Journal of Antimicrobial Chemotherapy. 1996;37(6):1155-1164. https://doi.org/10.1093/jac/37.6.1155
  34. Zettner EM, Gleser MA. Progressive hearing loss among patients with cystic fibrosis and parenteral aminoglycoside treatment. Otolaryngology — Head and Neck Surgery. 2018;159(5):887-894. Epub 2018 Jun 19. PMID: 29914288. https://doi.org/10.1177/0194599818782444
  35. Besser J, Festen JM, Goverts ST, Kramer SE, Pichora-Fuller MK. Speech-in-speech listening on the LiSN-S test by older adults with good audiograms depends on cognition and hearing acuity at high frequencies. Ear and Hearing. 2015;36(1):24-41.  https://doi.org/10.1097/AUD.0000000000000096
  36. Heffner HE, Heffner RS. High-frequency hearing. In: Dallos P, Oertel D, Hoy R, eds. Handbook of the Senses: Audition. Elsevier; 2008:55-60.  https://doi.org/10.1016/B978-012370880-9.00004-9
  37. Hirsch I, Davis H, Silverman S, Reynolds E, Eldert E, Benson R. Development of materials for speech audiometry. Journal of Speech and Hearing. 1952;17(3):321-337.  https://doi.org/10.1044/jshd.1703.321
  38. Jiang M, Karasawa T, Steyger PS. Aminoglycoside-induced cochleotoxicity: A review. Frontiers in Cellular Neuroscience. 2017 Oct 09; 11:308.  https://doi.org/10.3389/fncel.2017.00308
  39. Filippone EJ, Kraft WK, Farber JL. The nephrotoxicity of vancomycin. Clinical Pharmacology and Therapeutics. 2017;102(3): 459-469.  https://doi.org/10.1002/cpt.726
  40. Cutting GR, Engelhardt J, Zeitlin PL. Genetics and Pathophysiology of Cystic Fibrosis. In: Kendig’s Disorders of the Respiratory Tract in Children. Amsterdam, the Netherlands: Elsevier; 2019:757-768. 
  41. Lazrak A, Fu L, Bali V, Bartoszewski R, Rab A, Havasi V, Keiles S, Kappes J, Kumar R, Lefkowitz E. The silent codon change I507-ATC→ ATT contributes to the severity of the ΔF508 CFTR channel dysfunction. FASEB Journal. 2013;27(11):4630-4645. Epub 2013 Aug 01. PMID: 23907436; PMCID: PMC4046180. https://doi.org/10.1096/fj.13-227330
  42. Espel JC, Palac HL, Bharat A, Cullina J, Prickett M, Sala M, McColley SA, Jain M. The relationship between sweat chloride levels and mortality in cystic fibrosis varies by individual genotype. Journal of Cystic Fibrosis. 2018 Jan;17(1):34-42. Epub 2017 Dec 06. PMID: 29221674. https://doi.org/10.1016/j.jcf.2017.11.002
  43. Lopes-Pacheco M. CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine. Frontiers in Pharmacology. 2020;10:1662. https://doi.org/10.3389/fphar.2019.01662
  44. Clancy JP, Cotton CU, Donaldson SH, Solomon GM, VanDevanter DR, Boyle MP, Gentzsch M, Nick JA, Illek B, Wallenburg JC. CFTR modulator theratyping: Current status, gaps and future directions. Journal of Cystic Fibrosis. 2019;18:22-34.  https://doi.org/10.1016/j.jcf.2018.05.004
  45. Bell SC, De Boeck K, Amaral MD. New pharmacological approaches for cystic fibrosis: Promises, progress, pitfalls. Pharmacology and Therapeutics. 2015;145:19-34.  https://doi.org/10.1016/j.pharmthera.2014.06.005
  46. Li Q, Liu S, Ma X, Yu J. Effectiveness and Safety of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Children with Cystic Fibrosis: A Meta-Analysis. Frontiers in Pediatrics. 2022;10:937250. https://doi.org/10.3389/fped.2022.937250
  47. Elborn JS, Blasi F, Burgel P-R, Peckham D. Role of inhaled antibiotics in the era of highly effective CFTR modulators. European Respiratory Review. 2023;32(167):220154. https://doi.org/10.1183/16000617.0154-2022
  48. Taylor-Cousar JL, Robinson PD, Shteinberg M, Downey DG. CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis. Lancet. 2023;402(10408):1171-1184. Epub 2023 Sep 09. PMID: 37699418. https://doi.org/10.1016/s0140-6736(23)01609-4
  49. Hwang T-C, Yeh J-T, Zhang J, Yu Y-C, Yeh H-I, Destefano S. Structural mechanisms of CFTR function and dysfunction. Journal of General Physiology. 2018;150:539-570.  https://doi.org/10.1085/jgp.201711946
  50. Bernard A, Hermans C, Dom G, Terryn S, Leal T, Lebecque P, Cassiman J-J, Scholte BJ, de Jonge HR, Courtoy PJ. Cystic fibrosis is associated with a defect in apical receptor–mediated endocytosis in mouse and human kidney. Journal of the American Society of Nephrology. 2007;18:707-718.  https://doi.org/10.1681/ASN.2006030269
  51. Raggi C, Fujiwara K, Leal T, Jouret F, Devuyst O, Terryn S. Decreased renal accumulation of aminoglycoside reflects defective receptor-mediated endocytosis in cystic fibrosis and Dent’s disease. Pflugers Archiv: European Journal of Physiology. 2011;462:851-860.  https://doi.org/10.3389/fphar.2019.01662
  52. Ramananda Y, Naren AP, Arora K. Functional Consequences of CFTR Interactions in Cystic Fibrosis. International Journal of Molecular Sciences. 2024;25:3384. https://doi.org/10.3390/ijms25063384
  53. Levring J, Chen J. Structural identification of a selectivity filter in CFTR. Proceedings of the National Academy of Sciences of the United States of America. 2024 Feb 27;121(9):e2316673121. Epub 2024 Feb 21. PMID: 38381791; PMCID: PMC10907310. https://doi.org/10.1073/pnas.2316673121
  54. Kopp R, Krautloher A, Ramírez-Fernández A, Nicke A. P2X7 interactions and signaling: making head or tail of it. Frontiers in Molecular Neuroscience. 2019;12:183.  https://doi.org/10.3389/fnmol.2019.00183
  55. Alves LA, de Melo Reis RA, de Souza CA, de Freitas MS, Teixeira PC, Neto Moreira Ferreira D, Xavier RF. The P2X7 receptor: Shifting from a low- to a high-conductance channel — an enigmatic phenomenon? Biochimica et Biophysica Acta. 2014; 1838(10): 2578-2587. https://doi.org/10.1016/j.bbamem.2014.05.015
  56. Gabillard-Lefort C, Casey M, Glasgow AMA, Boland F, Kerr O, Marron E, Lyons AM, Gunaratnam C, McElvaney NG, Reeves EP. Trikafta Rescues CFTR and Lowers Monocyte P2X7R-induced Inflammasome Activation in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine. 2022; 205(7):783-794.  https://doi.org/10.1164/rccm.202106-1426oc
  57. Al-Malky G, Suri R, Dawson SJ, Sirimanna T, Kemp D. Aminoglycoside antibiotics cochleotoxicity in paediatric cystic fibrosis (CF) patients: A study using extended high-frequency audiometry and distortion product otoacoustic emissions. International Journal of Audiology. 2011;50(2):112-122.  https://doi.org/10.3109/14992027.2010.524253
  58. Thomsen J, Friis B, Jensen K, Bak-Pedersen K, Larsen PK. Tobramycin ototoxicity. Repeated courses of high dosage treatment in children with cystic fibrosis. Journal of Antimicrobial Chemotherapy. 1979;5(3):257-260.  https://doi.org/10.1093/jac/5.3.257
  59. Scheenstra RJ, Heijerman HG, Zuur CL, Touw DJ, Rijntjes E. No hearing loss after repeated courses of tobramycin in cystic fibrosis patients. Acta Oto-Laryngologica. 2010 Feb;130(2):253-258. PMID: 19479457. https://doi.org/10.3109/00016480903015150
  60. Garinis AC, Cross CP, Srikanth P, Carroll K, Feeney MP, Keefe DH, Hunter LL, Putterman DB, Cohen DM, Gold JA, Steyger PS. The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis. Journal of Cystic Fibrosis. 2017;16(3):401-409.  https://doi.org/10.1016/j.jcf.2017.01.006
  61. Polyakov DP, Daikhes NA, Bazanova MV, Melyanovskaya YuL. Assessment of the risk of hearing loss in children with cystic fibrosis. Russian Bulletin of Otorhinolaryngology. 2024;89(3):29-35. (In Russ.). https://doi.org/10.17116/otorino20248903129
  62. Forman-Franco B, Abramson AL, Gorvoy JD, Stein T. Cystic fibrosis and hearing loss. Archives of Otolaryngology — Head and Neck Surgery. 1979;105(6):338-342.  https://doi.org/10.1001/archotol.1979.00790180036007
  63. Stavroulaki P, Vossinakis IC, Dinopoulou D, Doudounakis S, Adamopoulos G, Apostolopoulos N. Otoacoustic emissions for monitoring aminoglycoside-induced ototoxicity in children with cystic fibrosis. Archives of Otolaryngology — Head and Neck Surgery. 2002;128(2):150-155.  https://doi.org/10.1001/archotol.128.2.150
  64. Pedersen SS, Jensen T, Osterhammel D, Osterhammel P. Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis. Antimicrobial Agents and Chemotherapy. 1987;31(4):594-599.  https://doi.org/10.1128/AAC.31.4.594
  65. Martins L, Camargos PA, Becker HM, Becker CG, Guimaraes RE. Hearing loss in cystic fibrosis. International Journal of Pediatric Otorhinolaryngology. 2010;74(5):469-473.  https://doi.org/10.1016/j.ijporl.2010.01.021
  66. Schneider-Futschik EK, Munro CB, Quinlan C, Ranganathan S. Investigating the Potential Hearing Impairment and Ototoxicity in Children up to Six Years With Cystic Fibrosis After Aminoglycoside Exposure (PIANO‐CF Extension). Pediatric Pulmonology. 2025;60(2):27505. https://doi.org/10.1002/ppul.27505
  67. Harruff EE, Kil J, Ortiz MGT. Ototoxicity in Cystic Fibrosis Patients Receiving Intravenous Tobramycin for Acute Pulmonary Exacerbation. Journal of Cystic Fibrosis. 2021;20(2):288-294.  https://doi.org/10.1016/j.jcf.2020.11.020
  68. Gleser MA, Zettner EM. Negative Hearing Effects of a Single Course of IV Aminoglycoside Therapy in Cystic Fibrosis Patients. International Journal of Audiology. 2018;57(12):923-930.  https://doi.org/10.1080/14992027.2018.1514537
  69. Aminoglycoside. In: Meyler’s Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions. Aronson JK, ed. 15th ed. Vol. 1. The Netherlands: Elsevier; 2006:118-136. 
  70. Kahlmeter G, Dahlager JI. Aminoglycoside Toxicity — A Review of Clinical Studies Published between 1975 and 1982. Journal of Antimicrobial Chemotherapy. 1984;13(Suppl A):9-22.  https://doi.org/10.1093/jac/13.suppl_a.9
  71. Massie J, Cranswick N. Pharmacokinetic Profile of once Daily Intravenous Tobramycin in Children with Cystic Fibrosis. Journal of Paediatrics and Child Health. 2006;42(10):601-605.  https://doi.org/10.1111/j.1440-1754.2006.00944.x
  72. WHO. Programme for the Prevention of Deafness and Hearing Impairment. In: Report of An Informal Consultation on Strategies for Prevention of Hearing Impairments from Ototoxic Drugs. 1995:21-23. 
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.